Topica Pharmaceuticals

Description

• Topica Pharmaceuticals, Inc. is a privately held pharmaceutical company focused on the clinical development of luliconazole for onychomycosis. Onychomycosis or nail fungus affects 32M patients in the US today. Due to the limitations of currently approved FDA treatments it is estimated that less than 3M patients receive treatment for this disease. TTopica holds an exclusive license for luliconazole in the America's and Europe. Luliconazole is currently approved in Japan where it is the leading topical prescription antifungal. In 2010 Topica sublicensed its luliconazole program for tinea infections (fungal infections of the skin) to Medicis, which has since been acquired by Valeant Pharmaceuticals. Valeant has filed an NDA for 1% luliconazole cream which is currently in review by the FDA with approval expected in late 2013. Luliconazole is the most potent antifungal molecule known against the most common fungal pathogens that cause nail fungus. Luliconazole is approximately 60 x more potent than the most potent treatment currently approved for onychomycosis (oral terbinafine). Topica's 10% Luliconazole Solution is currently being studied in a 334 patient phase 2b/3 trial that completed enrollment in June 13. Study results are expected in Q3'14. In a positive data scenario Topica will be seeking a partner for US and EU development and commercialization.
• 

  Headquarters:4300 El Camino Real Suite 101, Los Altos, California, United States

  More
• 

  Phone Number: +1 650-209-3700

• 

  Website: https://www.topicapharma.com

• 

  Employees:2

• 

  Revenue:$0 - 1M

• 

  Legal Name:Topica Pharmaceuticals

• Topica Pharmaceuticals's Social Media

  
• Is this data correct?

• |  NAICS Code: 325412  |

  Show More